Charter Hall Social Infrastructure REIT (CQE) has acquired a 25% interest in a $53 million Brisbane pathology lab leased to Sonic Healthcare under a 20-year triple-net lease, while divesting early learning assets and reaffirming FY26 guidance.
- 25% stake in $53 million Brisbane life science asset
- 20-year triple-net lease with Sonic Healthcare
- Early learning asset sales total $37.1 million at 4.6% yield
- FY26 earnings and distribution guidance reaffirmed
- Portfolio exposure to life sciences sector increased
Strategic Acquisition of Brisbane Pathology Laboratory
Charter Hall Social Infrastructure REIT (ASX:CQE) has taken a significant step into the life sciences sector by acquiring a 25% interest in a $53 million integrated pathology laboratory located in Bowen Hills, Brisbane. The asset, fully leased to Sonic Healthcare Limited (ASX:SHL), Australia’s largest pathology provider, is secured by a 20-year triple-net lease with annual CPI-linked rent reviews capped at 3.5%. This long-term lease arrangement adds a stable income stream backed by a tenant with a market capitalisation exceeding $9 billion.
The property serves as Sonic’s central laboratory for Queensland and parts of New South Wales and the Northern Territory. Developed between 2016 and 2024, it includes specialised laboratory fit-outs, diagnostic offices, and logistics facilities designed to handle high sample volumes. Strategically positioned just 1.7 kilometres from Brisbane’s CBD and close to major health and research precincts, the asset benefits from excellent connectivity to hospitals, public transport, and Brisbane Airport.
Portfolio Impact and Funding Strategy
CQE’s acquisition was executed via a sale and leaseback transaction involving Charter Hall Group’s newly established Charter Hall Inflation Protected Partnership 1 (CHIP1), which holds 100% of the asset. CQE’s 25% stake in CHIP1 was funded primarily through the ongoing divestment of early learning assets, illustrating the REIT’s active portfolio management approach.
This move increases CQE’s exposure to high-quality tenant covenants and modern social infrastructure assets, with income from long-weighted average lease expiry (WALE) non-early learning assets rising to 38%, up 3% on a pro-forma basis as of 31 December 2025. Fund Manager Travis Butcher highlighted the acquisition as a strategic enhancement of the portfolio, adding a leading healthcare operator and expanding CQE’s footprint in the life sciences sector.
Early Learning Asset Divestments and Financial Guidance
Since the end of 2025, CQE has contracted the sale of nine early learning assets totalling $37.14 million at an average yield of 4.6%, achieving a 3.4% premium to book value. This divestment aligns with the REIT’s strategy to curate its portfolio towards higher quality, longer WALE assets.
Amid these portfolio adjustments, CQE reaffirmed its FY26 earnings per unit (EPU) guidance of no less than 17.2 cents and distribution per unit (DPU) guidance of 17.0 cents. The June quarter distribution of 4.3 cents per unit translates to an annualised yield of 6.5% based on the current unit price of $2.65, maintaining an attractive income profile for investors.
Bottom Line?
CQE’s stake in a long-term, inflation-protected life science asset leased to a blue-chip tenant signals a deliberate pivot towards resilient income streams, but the impact of ongoing portfolio reshaping on future growth remains to be seen.
Questions in the middle?
- How will CQE’s partnership structure in CHIP1 evolve with additional capital partners?
- What are the long-term implications of increasing exposure to life sciences on portfolio risk and income stability?
- Will the divestment of early learning assets continue, and how might this affect overall portfolio diversification?